Emergent BioSolutions Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	788.9	1,044	1,049	1,118	1,774	1,577
Revenue Growth (YoY)	-29.91%	-0.54%	-6.10%	-36.99%	12.45%	42.61%
Cost of Revenue	404.6	732	795.1	827.4	980.4	714.2
Gross Profit	384.3	311.6	254.2	290.1	793.2	863.1
Selling, General & Admin	195.7	298.7	356.7	339.5	348.7	304.1
Amortization of Goodwill & Intangibles	65.1	65.1	65.6	59.9	58.5	59.8
Operating Expenses	260.4	363.8	422.3	399.4	407.2	363.9
Operating Income	123.9	-52.2	-168.1	-109.3	386	499.2
Interest Expense	-59.4	-71	-87.9	-37.3	-34.5	-31.3
Other Non Operating Income (Expenses)	59.6	13.1	8.9	-11.7	-3.7	4.7
EBT Excluding Unusual Items	124.1	-110.1	-247.1	-158.3	347.8	472.6
Merger & Restructuring Charges	-4.3	-55.9	-33.2	-51.4	-	-
Impairment of Goodwill	-	-	-218.2	-6.7	-41.7	-
Gain (Loss) on Sale of Assets	-12.2	24.3	74.2	-	-	-
Asset Writedown	-	-	-306.7	-	-	-29
Other Unusual Items	8.8	-1.2	-0.2	-2.6	-2.9	-31.7
Pretax Income	105.9	-142.9	-731.2	-219	303.2	411.9
Income Tax Expense	30	47.7	29.3	-7.4	83.7	106.1
Earnings From Continuing Operations	75.9	-190.6	-760.5	-211.6	219.5	305.8
Net Income	75.9	-190.6	-760.5	-211.6	219.5	305.8
Net Income to Common	75.9	-190.6	-760.5	-211.6	219.5	305.8
Net Income Growth	-	-	-	-	-28.22%	461.10%
Shares Outstanding (Basic)	54	53	51	50	54	53
Shares Outstanding (Diluted)	56	53	51	50	54	54
Shares Change (YoY)	6.86%	3.52%	2.20%	-7.39%	0.56%	2.67%
EPS (Basic)	1.41	-3.60	-14.85	-4.22	4.10	5.80
EPS (Diluted)	1.35	-3.60	-14.85	-4.22	4.06	5.68
EPS Growth	-	-	-	-	-28.52%	446.15%
Free Cash Flow	1.4	35.8	-257.9	-149.9	96.1	395
Free Cash Flow Per Share	0.03	0.68	-5.04	-2.99	1.78	7.34
Gross Margin	48.71%	29.86%	24.23%	25.96%	44.72%	54.72%
Operating Margin	15.71%	-5.00%	-16.02%	-9.78%	21.76%	31.65%
Profit Margin	9.62%	-18.26%	-72.48%	-18.93%	12.38%	19.39%
Free Cash Flow Margin	0.18%	3.43%	-24.58%	-13.41%	5.42%	25.04%
EBITDA	220	53.4	-47	15.7	504.2	609.2
EBITDA Margin	27.89%	5.12%	-4.48%	1.41%	28.43%	38.62%
D&A For EBITDA	96.1	105.6	121.1	125	118.2	110
EBIT	123.9	-52.2	-168.1	-109.3	386	499.2
EBIT Margin	15.71%	-5.00%	-16.02%	-9.78%	21.76%	31.65%
Effective Tax Rate	28.33%	-	-	-	27.61%	25.76%
Revenue as Reported	788.9	1,044	1,049	1,118	1,774	1,577

Source: S&P Global Market Intelligence. Standard template. Financial Sources.